卖什么
基于患者来源样本的AI药物发现平台。
商业模式拆解
触发点：什么让他们现在购买？
Company says 57% of clinical failures come from inadequate efficacy, motivating training on end-stage patient tissue.
工作流：什么输入变成什么输出？
Treatment-resistant patient tissue is grown into organoids, robotic imaging generates drug-response data, deep learning designs molecules, which are synthesized and tested with results fed back (400+ molecules per program).
经济账：省了什么，怎么收费？
Builds a pipeline of proprietary small-molecule assets across multiple disease areas (biotech asset model).
渠道：怎么接触到客户？
未核实Builds a proprietary small-molecule pipeline across three modalities; no partnering terms published.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-07-17 | — | €3M | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.